SCHEMBL4720928

SCHEMBL4720928

CCCOc1[nH]n[c]c1-c1cccc2ccccc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36
CHRNA7 P36544 1/20 0.36
BTK Q06187 1/20 0.36
ALOX15 P16050 1/20 0.36
HTR1B P28222 3/20 0.35
PDE5A O76074 4/20 0.35
KDM4E B2RXH2 1/20 0.35
HTR1D P28221 1/20 0.35
LMNA P02545 3/20 0.34
ALDH1A1 P00352 2/20 0.34
MAPT P10636 2/20 0.34
HTT P42858 2/20 0.34
MEN1 O00255 2/20 0.34
TSHR P16473 2/20 0.34
KMT2A Q03164 2/20 0.34
ATM Q13315 1/20 0.34
TDP1 Q9NUW8 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4724147 0.94 HTR1B (0.39) CNR1CNR2CHRNB4CHRNA3CHRNA7
SCHEMBL4724759 0.89 ENPP1 (0.39) CHRNB4CHRNA3CHRNA7ALOX15KDM4E
SCHEMBL4722365 0.82 KDM4E (0.38) CNR2ALOX15KDM4EALDH1A1MAPT
SCHEMBL4724605 0.77 MAPT (0.34) KDM4ELMNAALDH1A1MAPTHTT
SCHEMBL4722240 0.76 HTR1B (0.37) CNR1CNR2CHRNB4CHRNA3CHRNA7
SCHEMBL4721248 0.75 TLR8 (0.37) CNR1CNR2CHRNB4CHRNA3CHRNA7
SCHEMBL4724382 0.74 CNR1 (0.37) CNR1CNR2CHRNB4CHRNA3CHRNA7
SCHEMBL4724637 0.74 HTR1B (0.43) CNR1CNR2HTR1BPDE5AHTR1D
SCHEMBL4724526 0.74 S1PR1 (0.38) CNR1CNR2CHRNB4CHRNA3CHRNA7
SCHEMBL4719990 0.73 CNR1 (0.41) CNR1CNR2HTR1BPDE5AHTR1D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors PFIZER INC. 2008-07-24 US disclosed
EP-1874780-A1 4-PIPERAZINYLTHIENO[2,3-D]PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS Pharmacia & Upjohn Company LLC (US) 2008-01-09 EP disclosed
WO-2006100591-A1 4-PIPERAZINNYLTHIENO [2,3-D] PYRIMIDINE COMPOUNDS AS PLATELET AGGREGATION INHIBITORS PHARMACIA & UPJOHN COMPANY LLC (US) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176857-A1 4-Piperazinnylthieno[2,3-d]Pyrimidine Compounds as Platelet Aggregation Inhibitors TBXA2R, P2RY4, PF4 CNR1 318/4885CNR2 385/4885CHRNB4 1234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.